Hims & Hers Health, Inc. Class A (HIMS)

The stock experienced a 15.8% drop on October 17, 2025, due to market uncertainty and regulatory headwinds concerning compounded obesity drugs. CEO Andrew Dudum sold $11 million worth of company stock on October 17, 2025, contributing to the stock's decline. The announcement of expanded women's health offerings, specifically a Menopause and Perimenopause specialty, ignited a double-digit rally in its stock. CEO Andrew Dudum sold over $33 million worth of company stock on August 14, 2025, which caused shares to tumble nearly 4%. The Q2 2025 earnings report showed a sequential decline in both revenue and average revenue per user (ARPU), and subscriber growth that was flat quarter-over-quarter, leading to investor concern and an initial double-digit slump in shares. Stock volatility in early September 2025 reflected mixed investor sentiment amid macroeconomic uncertainty and shifting GLP-1 demand dynamics. The stock experienced a 35% crash during the week of June 26, 2025, after a joint venture with Novo Nordisk to sell a branded weight-loss drug fell apart, with Novo Nordisk accusing Hims & Hers of false advertising and endangering patients.

While the company's core offerings are generally considered non-seasonal, the Q2 2025 earnings report showed a sequential decline in revenue and average revenue per user, which some analysts suggested might challenge the company's claim of low seasonality. The company's CFO mentioned plans to increase marketing spending in Q3 to address "seasonality headwinds," implying that some seasonal fluctuations in demand do exist.

Hims & Hers Health, Inc. operates a digital health platform connecting consumers with licensed healthcare professionals in the online pharmacy and telehealth sectors. The company uses a direct-to-consumer business model, providing prescription and non-prescription health and wellness products and services through its digital platforms. Its major product categories include sexual health, hair care, weight loss, mental health, dermatology, and primary care, with recent expansion into menopause and perimenopause care. The company aims to enhance healthcare accessibility and convenience by delivering personalized treatment plans and products directly to consumers.

Hims & Hers Health, Inc. primarily operates in the United States, which accounts for over 95% of its total revenue. The company has expanded its telehealth services to the United Kingdom and is headquartered in San Francisco, California.

Hims & Hers Health, Inc.'s brand reputation has faced scrutiny in the past year, particularly after a Super Bowl advertisement was criticized for being misleading and failing to adequately disclose side effects. The company has launched initiatives such as the Community Member Council and the Health Collective to enhance customer involvement and inform platform and product development.

Institutional investors hold approximately 78.7% of Hims & Hers Health, Inc.'s shares, while individual insiders hold about 9.62%. CFO Oluyemi Okupe and CEO Andrew Dudum have collectively sold over $41 million worth of shares in recent transactions.